Clinigen in the news
global ethical medicine access
Tamtam found 13 recent articles about Clinigen.
- Clinigen Appoints Greg Skalicky as Chief Executive Officer
Greg Skalicky has been appointed Group CEO of Clinigen, effective July 20, 2026, bringing extensive leadership experience to drive the company's global growth and critical medicine access initiatives.
- Clinigen exec on the human side of patient access
A Clinigen Group executive discusses the challenging yet rewarding human aspect of ensuring patients globally receive critical, life-saving medicines under tight deadlines and complex regulations.
- Shaun Chilton to take over as Chief Executive at Clinigen
Clinigen Group appoints Shaun Chilton as CEO to replace Peter George following a period of significant revenue growth and market expansion.
- Amulet Capital Sells SSI Strategy To Clinigen
Amulet Capital Partners sold its healthcare consulting firm, SSI Strategy, to Clinigen, a global company focused on medicine access.
- Clinigen to Acquire SSI Strategy
Clinigen is acquiring SSI Strategy to expand its strategic consulting and global operational services for the biopharma industry.
- Acquisition of SSI Strategy by Clinigen
Clinigen Group has acquired SSI Strategy to expand its biopharma services and global medicine access capabilities with advisory support from BDO.
- Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
Clinigen is divesting its Proleukin drug to Iovance Biotherapeutics for £166.7 million to refocus on its core pharmaceutical services business.
- White & Case Advises Triton on £1.2 Billion Recommended Takeover of Clinigen Group plc
Triton is acquiring Clinigen Group for £1.2 billion to expand its private equity portfolio in the pharmaceutical services sector.
- Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited
Secura Bio partnered with Clinigen to distribute and commercialize the blood cancer treatment COPIKTRA across 39 European nations.
- Clinigen Launches Malaysia Office to Strengthen Presence in Southeast Asia
Clinigen Group has expanded its Southeast Asian presence by opening a new operational office in Kuala Lumpur to improve regional medicine access.
- Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Sarepta Therapeutics and Clinigen launched a managed access program to provide the drug eteplirsen to eligible Duchenne muscular dystrophy patients in international markets.
- Clinigen’s role in global specialty pharmaceuticals
Clinigen Group provides global specialty pharmaceutical services and manages the ethical distribution of unlicensed and niche medicines to patients with unmet medical needs.
- Clinigen Group’s £225m acquisition of Idis supported by £106m in funding from Santander, RBS and HSBC
Clinigen Group acquired Idis Group Holdings for £225 million to become the market leader in global ethical unlicensed medicine supply.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Clinigen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies